News

Amarna to develop immunotherapies
Enlarge image

Personalised MedicineNetherlandsBelgiumSpain

Amarna to develop immunotherapies

02.07.2015 - Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

Amarna Therapeutics is the latest biotech to move into the development of immunotherapies, which hold great potential for the treatment of a wide range of diseases, including cancer. Founded in 2008, the Leiden-based biotech has entered into a cooperation with Austrian Center for Biomarker Research in Medicine (CBmed). The objective of the collaboration is to develop and test Amarna’s viral gene delivery vector platform SVac for its capacity to modulate immune responses in humans with the final aim to develop efficient treatment options for many disease areas, including acute lymphoblastic leukaemia, obesity, diabetes mellitus type 2 and atherosclerotic cardiovascular disease.

The agreement includes the design, development and testing in two separate projects of a CAR T cell therapy and reverse vaccines for the treatment of these diseases with high unmet clinical needs. CAR T therapies boost the immune system of cancer patients by genetically engineering the patient’s T cells to produce special receptors on their surface. These receptors are proteins called chimeric antigen receptors (CARs), which allow the T cells to recognise antigens on tumour cells. Reverse vaccines reduce levels of immune cells believed responsible for certain types of degenerative diseases e.g. diabetes type 2. Amarna, which has its research facility in Seville Spain, will contribute its SVac platform to the collaboration, and CBmed will perform in vitro and in vivo preclinical R&D and develop immunological assays in its core laboratory.

"Biomarkers play a crucial role in the development of new therapeutic and preventive agents. This cooperation is a wonderful opportunity for CBmed to investigate novel biomarkers alongside the identification of new therapeutic targets,” commented Thomas Pieber, Chief Scientific Officer of CBmed.

The financial terms of the deal have not been disclosed.


© european-biotechnology-news.com/jc

http://www.european-biotechnology-news.com/news/news/2015-03/amarna-to-develop-immunotherapies.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news.html?cHash=8190681cb0ea9c9ddcb48c4293a426da&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BAVARIAN NORDIC (D)44.62 EUR12.34%
  • MOLOGEN (D)5.20 EUR7.00%
  • BRITISH TECHNOLOGY GROUP (UK)686.00 GBP6.94%

FLOP

  • CYTOS (CH)0.50 CHF-9.09%
  • NOVACYT (F)4.99 EUR-6.90%
  • EPIGENOMICS (D)5.12 EUR-5.19%

TOP

  • DBV Technologies (F)54.26 EUR26.8%
  • VERONA PHARMA (UK)5.10 GBP17.2%
  • MEDIGENE (D)9.72 EUR16.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.80 EUR-26.9%
  • NORDIC NANOVECTOR (N)25.50 NOK-25.9%

TOP

  • ADOCIA (F)66.29 EUR388.1%
  • 4SC (D)4.90 EUR375.7%
  • VERONA PHARMA (UK)5.10 GBP314.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.00 SEK-70.1%
  • NEOVACS (F)1.14 EUR-69.1%

No liability assumed, Date: 02.07.2015